SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

CRL revs boosted by Argenta and Biofocus; buys ChanTest

30-Oct-2014 - Weaker demand in Europe and Japan saw revenue from Charles River Laboratories' animal models business decline in Q3, but Argenta and BioFocus boosted discovery sales.

MPI Research pushes further into early phase development with CRO acquisition

28-Oct-2014 - MPI Research announced Monday it has acquired the assets of Kalamazoo, Michigan-based CRO Jasper Clinical Research & Development, which provides early-stage human clinical testing of new drugs for an undisclosed amount....

Tail-ored to patients: Horizon latest CRO to offer PDX mouse models

23-Oct-2014 - Horizon is already making plans for the research model company it acquired last month, announcing today it will offer patient-derived xenograft (PDX) models for breast cancer under the Sage Labs...

Mouse model firm Crown builds oncology centre

22-Oct-2014 - Animal-model contract research organisation (CRO) Crown Bioscience will open a research centre in North Carolina, combining expanded oncology services with its existing cardiovascular and metabolic offerings.

MedImmune teams with UK academics on neurodegenerative disease research

16-Oct-2014 - MedImmune’s neurodegenerative disease partnership with the University of Cambridge is about working with “great scientists with great brains” according to a spokeswoman for parent company, AstraZeneca.

Thermo Scientific assesses PK/PD analysis tool after study shows bioequivalence data discrepancies

14-Oct-2014 - Thermo Scientific is assessing its PK/PD data analysis software after a technical paper found discrepancies in results that may have affected drug approvals.

Some positive milestone news for Evotec: Bayer collaboration enters animal testing

01-Oct-2014 - Evotec has announced positive milestone news this week, revealing that efforts to develop an endometriosis drug with Bayer have moved into preclinical testing.

Horizon buys Sage for $48m as BIg Pharma turns to personalised medicines for increased return on investment

29-Sep-2014 - Merck KGaA’s acquisition of Sigma-Aldrich is testament to Big Pharma’s growing interest in personalized medicine says Horizon Discovery, which has bought Sage Labs for $48m (€38m).

More acquisitions on the 'Horizon' says UK drug discovery services firm CEO post IPO

24-Sep-2014 - Newly public Horizon Discovery Group says it is looking for more acquisitions to become a fully integrated products, services and research provider as revenues soars 35%.

Feature

Nobel prizes and the world’s top drug: a gallery of Scottish pharma

17-Sep-2014 - On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a look at the pharma inventions Scotland gave the world.

CRL on the prowl for Chinese M&As in world’s future science hub

16-Sep-2014 - Charles River Labs (CRL) has singled out China as an area of “disproportionate growth” in biologics R&D and says it is on the hunt for preclinical acquisitions in the region....

CRL plans M&As ahead of surge in discovery outsourcing

15-Sep-2014 - Half of drug discovery will eventually be outsourced as the service area goes the way of contract toxicology, according to the CEO of Charles River Laboratories (CRL).

Charles River to lay off up to 30 employees following NCI contract termination

08-Sep-2014 - Early phase CRO (contract research organization) Charles River Laboratories will lay off between 26 and 30 employees following the US National Cancer Institute’s decision to terminate a contract in which...

Shifting pipelines drive AMRI to expand protein expression services

05-Sep-2014 - AMRI has added protein expression and purification services to its drug discovery services citing the shift in pipelines towards larger molecule drugs as a driver.

Layoffs possible as Ricerca Biosciences in discussions to be acquired, CEO says

03-Sep-2014 - Ohio-based CRO (contract research organization) Ricerca Biosciences is holding “ongoing discussions with several parties” about the possible sale of one or more of its divisions or the entire company, CEO...

Zirconium best for imaging mAbs but needs programme, say European orgs

02-Sep-2014 - European organisations representing academic CROs and nuclear medicine researchers have established an accreditation programme for a novel Zirconium-PET imaging technique, used in early development of monoclonal antibodies.

Crown Bio: New in vitro technology could revolutionise drug discovery

02-Sep-2014 - Increasing the predictivity of in vitro systems could cut the costs of drug development and shift preclinical research away from animal models, according to Crown Bioscience.

Breed lab mice with wild for better neuro research say scientists

29-Aug-2014 - The drive for homogenous animal models in preclinical research has robbed mice of useful behavioural traits, say scientists.

Harlan looks to corner NCI grantees lost by Charles River

21-Aug-2014 - News of the discontinuation of the National Cancer Institute’s (NCI) Animal Production Program has led Charles River Laboratories rival Harlan to vie for the market of grantees that still need...

How to speed up development: share work with rivals, say scientists

21-Aug-2014 - Drug developers should add their early-stage discoveries to an open-source database or pay a fine to cut wasted time duplicating results, say researchers.

Organovo: 3D printed liver tissue to challenge current toxicity models

20-Aug-2014 - A 3D printed human liver system could offer better informed risk-based decisions earlier in the drug development process than with current in vitro models, according to developers Organovo.

What’s next for gene editing? After ‘knock-out’, time for ‘knock-in’

19-Aug-2014 - Horizon Discovery says the gene editing tool CRISPR used to engineer its human cell lines is exploding the possibilities of screening for preclinical customers.

Evotec teams with Shire on Fabry's disease as pharma interest in orphans grows

13-Aug-2014 - Evotec has partnered with Shire to develop inhibitors against Fabry’s disease and says such collaborations will grow as Big Pharma increasingly looks towards rare diseases.

CRL nears 85% capacity use, but says sector pricing won't improve yet

11-Aug-2014 - Charles River Laboratories is approaching its optimal capacity utilisation but says pricing will not improve until the rest of the preclinical CRO industry follows suit.

Biosimilar preclinical demand growing as US market beckons, says Harlan

07-Aug-2014 - US demand for biosimilar preclinical services is expected to rocket on the back of the US FDA’s acceptance of Sandoz’s biosimilar filing, according to Harlan Laboratories.